Greenwich LifeSciences, Inc.

GLSINASDAQ • USD
14.94 USD
↘ 0.34 (2.23%)AT CLOSE (03:59 PM EST)
15.61
↗ 0.67 (4.48%)
POST MARKET (AS OF 07:50 PM EST)
Post Market
AS OF 07:50 PM EST
15.61
↗ 0.67 (4.48%)
🔴Market: CLOSED

GLSI is currently priced at $14.94. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 13, 2026.

Open?$15.87
High?$15.87
Low?$14.56
Prev. Close?$15.28
Volume?75.3K
Avg. Volume?133.4K
VWAP?$14.94
Rel. Volume?0.56x
Bid / Ask
Bid?$15.23 × 300
Ask?$15.61 × 100
Spread?$0.38
Midpoint?$15.42
Valuation & Ratios
Market Cap?219.3M
Shares Out?14.7M
Float?6.3M
Float %?43.2%
P/E Ratio?N/A
P/B Ratio?70.35
EPS?-$1.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Employees
13
Market Cap
219.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-09-25
Address
3992 BLUEBONNET DR, BUILDING 14
STAFFORD, TX 77477
Phone: 203-434-3290
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
2
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.12Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.89%Squeeze Risk
Short Interest?1.6M
Days to Cover?12.5
Free Float6.3M
Avg Daily Volume126.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.54Adequate
Quick Ratio?1.54Adequate
Cash Ratio?1.54Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
70.35HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-9.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-695.6%WEAK▾
ROA?
S&P
3
-244.3%WEAK▾
Cash Flow & Enterprise
FCF?$-12488140
Enterprise Value?$210.4M
Fundamentals ratios updated end of day